The Bidens (@WhiteHouse) announce initiatives on health inequity and DARPA-like research for cancer. On a visit to @VCUMassey, @FLOTUS issued a presidential call to action on reducing #health inequities, #cancerdisparities. — https://t.co/MzyMOWsfOU
Cancer is a force of nature, relentless. Sometimes we are knocked down. Sometimes we cry.
People beat nature. We are relentless. We are the force of nature. We get up. We will never give up.
@LeciaSequist@oncoOuLungCA @ALKLungCancer I'm not sure... five ALK TKIs developed btwn crizotinib(13) and lotlatinib(18) and more TKIs in clinical trials VS erlotinib(05), afatinib(13), osimertinib(15) and no next generation TKIs in clinical trials
#ASCO21 theme is “Equity: every patient. Every day. Everywhere.” Patient advocates can register for free! Those who are ASCO members can register on mtg website. Nonmembers need to submit CV, bio-sketch, or resume to [email protected]#lcsm#bcsm#btsm#gyncsm#mmsm
Great story. I strong suspect that optimizing the dose of drug is low hanging fruit to improving survival in EGFR lung cancer. Speaking from experience. @EGFRResisters#lcsm
I would like to share the story of how a patient with cancer came up with the idea for a randomized trial, & how listening to him saved a lot of lives.
1/ In 2002, I had just completed a randomized trial with the notorious drug thalidomide for the cancer, multiple myeloma.
Last week, I received some difficult news - progressive leptomeningeal disease.
Yesterday, I played pretend tea time with Mia. Seeing her imagination was incredible.
We will never give up hope.
@Martha__Carlson I’ve felt this pain for years. Finally discovered Twitter’s mute feature. But I still question why a doctor so consistently, consequentually, wrong is so popular.
Large number of EGFR trials in China with almonertinib, a Chinese 3rd gen EGFR TKI. Unlike earlier Chinese EGFR TKI's this one seems as good as Tagrisso (maybe a little better toxicity). US rights owned by @EQRxINC.
https://t.co/c6GQwKsMqR